Intervention

toremifene

ClinicalTrials.gov intervention label

Clinical trials6

Recruiting0

Common conditions8

Lead sponsors shown4

Clinical trials

6 shown

Comparative Evaluation of Efficacy and Safety of Toremifene, Tamoxifen, and Aromatase Inhibitor Plus Ovarian Function Suppression in Hormone Receptor-Positive Early Breast Cancer Among Non-Low-Risk Premenopausal Women: A Real-World StudyNCT05801705 · 2023-06-01

Treatment and Survival Continuation Study of Atamestane Plus Toremifene vs Letrozole in Advanced Breast CancerNCT00267553 · 2005-11-01

Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast CancerNCT00044291 · 2002-06-01

Toremifene Followed by Radical Prostatectomy in Treating Patients With Stage I or Stage II Prostate CancerNCT00020735 · 2001-04-01

Toremifene With or Without Atamestane in Treating Postmenopausal Women With Metastatic Breast CancerNCT00010322 · 2000-10-01

Hormone Therapy and Chemotherapy in Treating Perimenopausal or Postmenopausal Women With Node-Positive Breast CancerNCT00002529 · 1993-05-01

Common conditions

Breast Cancer2 Breast Neoplasms2 Neoplasms, Hormone-dependent2 Breast Cancer Patients at Intermediate to High Risk1 Hormone-receptor-positive Breast Cancer1 Ovarian Function Suppression Combined With Aromatase Inhibitor or Tamoxifen or Torimefen1 Premenopausal Breast Cancer1 Prostate Cancer1

Leading sponsors

Intarcia Therapeutics3 ETOP IBCSG Partners Foundation1 Joel Nelson, MD1 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University1

Trial status mix

COMPLETED3

TERMINATED2

UNKNOWN1

Phase mix

PHASE34

PHASE21

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.